Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Depreciation and Amortization

Last Annual Value

285.05K

3-Year CAGR

-4%

5-Year CAGR

26%

10-Year CAGR

%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Depreciation and Amortization

NTRB · NASDAQ
CompanyDepreciation and Amortization
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
285.05K
-0.3%-2.2%N/A 
2.87M
-18.8%-2.9%N/A
0.00
N/AN/AN/A
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
1.69M
-1.1%-8.6%9.2%
919.00K
19.7%90.1%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
2.29M
-27.9%8.3%-15.2%
94.05K
4.0%43.4%N/A
5.12M
-8.5%6.6%61.7%
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
8.58M
-0.2%15.3%56.1%
IMA logo
ImageneBio Inc
NASDAQ:IMA
328.00K
-31.5%-9.6%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
168.00K
14.8%14.6%-21.1%
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15